Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-G1.1-NN Dose-Optimization in Healthy Volunteers
NCT03125473Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Drug Delivery Systems, Vaccines & Immunotherapeutics, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VXA-GI.1.NN in norovirus gastroenteritis (4 arms), sponsored by Vaxart, Inc. Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2017; status: completed.
02
Drugs
VXA-GI.1.NN
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT03125473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125473.